Who owns GSK? Superinvestor holders
11 superinvestors of the 157 tracked here hold GSK in their latest 13F filing, with $5.5B between them. Dodge & Cox team gives it the most weight: 1.12% of the reported portfolio.
Brandon Haley and Sarah Ketterer sold out of it in their latest quarter.
Key facts
- Superinvestors holding it
- 11 of 157
- Biggest holder
- Dodge & Cox team, $2.1B
- Largest weight
- Dodge & Cox team, 1.12%of their portfolio
- Combined value
- $5.5B
- Bought last quarter
- 5
- Sold last quarter
- 8
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox teamDodge & Cox | 1.12% | $2.1B | 43.18M | ▼ Reduced 10% | −5.01M | Q3 2026 |
| 2 | Thomas KahnKahn Brothers | 0.91% | $5.5M | 113.55K | ▼ Reduced 28% | −44.89K | Q3 2026 |
| 3 | Primecap teamPrimecap Management | 0.75% | $1.2B | 25.19M | ▲ Added 0.04% | +10.07K | Q3 2026 |
| 4 | Charles Brandes (founder)Brandes Investment Partners | 0.50% | $72.2M | 1.5M | ▲ Added 1.0% | +15.28K | Q3 2026 |
| 5 | Ken FisherFisher Investments | 0.49% | $1.7B | 35.35M | ▼ Reduced 1.0% | −371.52K | Q3 2026 |
| 6 | Jeremy Grantham (co-founder)GMO (Grantham, Mayo, Van Otterloo) | 0.41% | $188.7M | 3.92M | ▲ Added 8.9% | +318.55K | Q3 2026 |
| 7 | Tweedy, Browne teamTweedy, Browne Company | 0.30% | $3.7M | 77.44K | ▼ Reduced 5.0% | −4.08K | Q3 2026 |
| 8 | Steve CohenPoint72 Asset Management | 0.21% | $139.1M | 2.65M | New | +2.65M | Q2 2026 |
| 9 | Howard GleicherAristotle Capital Management | 0.12% | $53.9M | 1.12M | ▼ Reduced 24% | −344.66K | Q3 2026 |
| 10 | Murray StahlHorizon Kinetics | 0.01% | $1.1M | 23K | ▼ Reduced 4.4% | −1.05K | Q3 2026 |
| 11 | Richard PzenaPzena Investment Management | 0.00% | $1.4M | 28.96K | ▲ Added 18% | +4.46K | Q3 2026 |
Sold out last quarter
- Brandon Haleywas $304.6M · Q2 2026
- Sarah Kettererwas $375.5K · Q3 2026
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 10 | 110.51M | $5.3B | 4 | 7 |
| Q2 2026 | 157 | 12 | 118.6M | $6.2B | 5 | 8 |
| Q1 2026 | 157 | 13 | 131.41M | $7.3B | 4 | 10 |
| Q4 2025 | 157 | 12 | 143.46M | $7B | 5 | 6 |
| Q3 2025 | 157 | 12 | 152.48M | $6.6B | 6 | 6 |
| Q2 2025 | 157 | 13 | 152.68M | $5.9B | 8 | 4 |
| Q1 2025 | 156 | 12 | 148.46M | $5.8B | 7 | 5 |
| Q4 2024 | 156 | 10 | 123.96M | $4.2B | 7 | 3 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Dodge & Cox team | 43.18M | 48.2M | 58.66M | 68.52M | 78.4M | 78.76M | 78.65M | 68.44M |
| Ken Fisher | 35.35M | 35.72M | 34.52M | 33.2M | 32.23M | 31.34M | 30.03M | 18.84M |
| Primecap team | 25.19M | 25.18M | 25.2M | 25.13M | 25.77M | 27.73M | 25.71M | 25.26M |
| Jeremy Grantham (co-founder) | 3.92M | 3.6M | 3.52M | 3.49M | 2.57M | 2.6M | 2.14M | 4.15M |
| Charles Brandes (founder) | 1.5M | 1.48M | 1.45M | 1.72M | 1.87M | 1.77M | 1.68M | 1.36M |
| Howard Gleicher | 1.12M | 1.46M | 1.53M | 1.56M | 1.61M | 1.63M | 1.68M | 1.6M |
| Thomas Kahn | 113.55K | 158.44K | 160.98K | 178.7K | 260.84K | 659.87K | 822.23K | 884.71K |
| Tweedy, Browne team | 77.44K | 81.53K | 81.79K | 82.24K | 82.24K | 86.87K | 90.55K | 93.82K |
| Richard Pzena | 28.96K | 24.51K | 18.82K | 13.44K | 8.72K | 7.51K | — | — |
| Murray Stahl | 23K | 24.05K | 24.42K | — | — | 37.39K | 38.67K | — |
| Steve Cohen | · | 2.65M | — | — | — | — | — | — |
| Sarah Ketterer | — | 7.16K | 11.11K | 33.9K | 1.18M | 1.11M | 1.11M | 1.08M |
| Brandon Haley | · | — | 5.52M | 8.12M | 7.1M | 5.61M | 5.31M | — |
| Ray Dalio (founder) | · | — | 698.67K | 1.42M | 1.4M | 1.34M | 1.2M | 2.25M |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own GSK?
In their latest 13F filings: Dodge & Cox team (1.12% of the portfolio, $2.1B), Thomas Kahn (0.91% of the portfolio, $5.5M), Primecap team (0.75% of the portfolio, $1.2B), Charles Brandes (founder) (0.50% of the portfolio, $72.2M), Ken Fisher (0.49% of the portfolio, $1.7B), Jeremy Grantham (co-founder) (0.41% of the portfolio, $188.7M), Tweedy, Browne team (0.30% of the portfolio, $3.7M), Steve Cohen (0.21% of the portfolio, $139.1M), and 3 more.
Who bought GSK last quarter?
Primecap team (added 0.0%), Charles Brandes (founder) (added 1.0%), Jeremy Grantham (co-founder) (added 8.9%), Steve Cohen (new position), Richard Pzena (added 18%). “Last quarter” is each investor's latest reported quarter.
Who sold GSK last quarter?
Reduced: Dodge & Cox team (10% fewer shares), Thomas Kahn (28% fewer shares), Ken Fisher (1.0% fewer shares), Tweedy, Browne team (5.0% fewer shares), Howard Gleicher (24% fewer shares), Murray Stahl (4.4% fewer shares). Sold out entirely: Brandon Haley (was $304.6M), Sarah Ketterer (was $375.5K).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns GSK? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/GSK/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to GSK by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.